Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2008; 133(45): 2345-2348
DOI: 10.1055/s-0028-1100926
DOI: 10.1055/s-0028-1100926
Arzneimittel und Pharmakotherapie | Review article
Pharmakologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York
Posaconazol: Ein weiteres Triazol-Antimykotikum der neuen Generation?
Posaconazole: Another triazole antifungal of the new generation?Further Information
Publication History
eingereicht: 18.4.2008
akzeptiert: 11.9.2008
Publication Date:
28 October 2008 (online)
![](https://www.thieme-connect.de/media/dmw/200845/lookinside/thumbnails/10.1055-s-0028-1100926-1.jpg)
Schlüsselwörter
Posaconazol - Triazolantimykotikum - Hämato-Onkologie - Lanosterol-14α-Demethylase - Cytochrom-P450-Enzyme - Pharmakokinetik - Arzneimittelinteraktionen
Keywords
Posaconazole - triazole antifungal drug - hemato-oncology - lanosterol-14α-demethylase - cytochrome-P450-enzyme - pharmacokinetics - drug-drug-interactions
Literatur
- 1 Aktories F. et al .Allgemeine und spezielle Pharmakologie und Toxikologie. München; Urban & Fischer 2005
- 2 Cornely O A. et al . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356 348-359
- 3 Fachinformation zu Noxafil® SEB. 2007, Oktober
- 4 Hof H. A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006; 49 Suppl 1 2-6
- 5 Keating G M. Posaconazole. Drugs. 2005; 65 1553-1567; discussion 1568 – 1559
- 6 Muller C. et al . HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses. 2006; 49 Suppl 1 17-22
- 7 Pitisuttithum P. et al . Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005; 56 745-755
- 8 Raad II. et al . Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006; 42 1726-1734
- 9 Raad II. et al . Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia. 2008; 22 496-503
- 10 Smith J. et al . Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008; 30 167-172
- 11 Ullmann A J. et al . Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006; 50 658-666
- 12 Ullmann A J. et al . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356 335-347
- 13 Walsh T J. et al . Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007; 44 2-12
- 14 Wexler D. et al . Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004; 21 645-653
Dr. med. Carsten Müller
Institut für Pharmakologie, Universität
zu Köln
Gleueler Str. 24
50931 Köln
Phone: 0221/478-5066
Fax: 0221/478-7184
Email: c.mueller@uni-koeln.de